Australia · Delayed Price · Currency is AUD Ceryvyn Therapeutics Statistics
Total Valuation
ASX:CYV has a market cap or net worth of AUD 17.78 million. The enterprise value is -12.24 million.
| Market Cap | 17.78M |
| Enterprise Value | -12.24M |
Important Dates
The next estimated earnings date is Thursday, November 26, 2026.
| Earnings Date | Nov 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ASX:CYV has 1.37 billion shares outstanding. The number of shares has increased by 10.23% in one year.
| Current Share Class | 1.37B |
| Shares Outstanding | 1.37B |
| Shares Change (YoY) | +10.23% |
| Shares Change (QoQ) | +2.71% |
| Owned by Insiders (%) | 12.13% |
| Owned by Institutions (%) | 14.32% |
| Float | 980.22M |
Valuation Ratios
The trailing PE ratio is 0.05.
| PE Ratio | 0.05 |
| Forward PE | n/a |
| PS Ratio | 17,783.72 |
| PB Ratio | 0.60 |
| P/TBV Ratio | 0.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.78
| Current Ratio | 13.78 |
| Quick Ratio | 13.43 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.08 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -12.59% |
| Return on Invested Capital (ROIC) | -14.98% |
| Return on Capital Employed (ROCE) | -40.34% |
| Weighted Average Cost of Capital (WACC) | 12.36% |
| Revenue Per Employee | 30 |
| Profits Per Employee | 10.01M |
| Employee Count | 33 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -209,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 1.48 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 68.79 |
| Average Volume (20 Days) | 10,115,189 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ASX:CYV had revenue of AUD 1,000 and earned 330.45 million in profits. Earnings per share was 0.24.
| Revenue | 1,000 |
| Gross Profit | 1,000 |
| Operating Income | -11.95M |
| Pretax Income | 330.24M |
| Net Income | 330.45M |
| EBITDA | -11.94M |
| EBIT | -11.95M |
| Earnings Per Share (EPS) | 0.24 |
Balance Sheet
The company has 30.02 million in cash and no debt, with a net cash position of 30.02 million or 0.02 per share.
| Cash & Cash Equivalents | 30.02M |
| Total Debt | n/a |
| Net Cash | 30.02M |
| Net Cash Per Share | 0.02 |
| Equity (Book Value) | 29.62M |
| Book Value Per Share | 0.02 |
| Working Capital | 29.62M |
Cash Flow
| Operating Cash Flow | -12.50M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 10,000 |
| Net Borrowing | -30.89M |
| Free Cash Flow | -12.50M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 100.00%, with operating and profit margins of -1,194,700.00% and 33,044,500.00%.
| Gross Margin | 100.00% |
| Operating Margin | -1,194,700.00% |
| Pretax Margin | 33,023,600.00% |
| Profit Margin | 33,044,500.00% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ASX:CYV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -10.23% |
| Shareholder Yield | -10.23% |
| Earnings Yield | 1,858.13% |
| FCF Yield | -70.28% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ASX:CYV has an Altman Z-Score of -28.41 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -28.41 |
| Piotroski F-Score | 2 |